 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Agilent to Strengthen Personalized Rx Foothold with $2.2B Dako Acquisition
May 23, 2012
Agilent to Strengthen Personalized Rx Foothold with $2.2B Dako Acquisition
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - 20/20 GeneSystems Developing mTOR Pathway Test to Predict Herceptin Response in HER2-Positive Patients
September 19, 2012 / Pharmacogenomics Reporter - FDA Speeds New HER2-Targeted Drug and Companion Tests to Market
June 13, 2012 / Pharmacogenomics Reporter - Q&A: Diaceutics CEO Keeling Provides Personalized Rx-Focused Consultant's View of Industry Progress
February 22, 2012 / Pharmacogenomics Reporter - Mayo Study Finds Expanded Protein Panel Fails to Predict Outcome of Herceptin Treatment
December 16, 2011 / ProteoMonitor